The historical rank and industry rank for Aclaris Therapeutics's FCF Margin % or its related term are showing as below:
ACRS'
s FCF Margin % Range Over the Past 10 Years
Min: -3321.33 Med: -603.42 Max: -229.13
Current: -614.95
During the past 13 years, the highest FCF Margin % of Aclaris Therapeutics was -229.13%. The lowest was -3321.33%. And the median was -603.42%.
ACRS's FCF Margin % is ranked worse than 74.48% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs ACRS: -614.95
Aclaris Therapeutics FCF Margin % Related Terms
Aclaris Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aclaris Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (ACRS) has a FCF Margin % of -909.92% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aclaris Therapeutics and its competitors. According to the industry distribution chart, Aclaris Therapeutics ranks #715 out of 960 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Aclaris Therapeutics' FCF Margin % too high?
Aclaris Therapeutics' current FCF Margin % is -909.92%. Based on the distribution chart, Aclaris Therapeutics ranks #715 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' FCF Margin % compare to IMMX and PRME?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #715 out of 960 companies for FCF Margin %. This places Aclaris Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current FCF Margin % is -909.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $4.85 — trading 976.7% above its estimated fair value. The current FCF Margin % is -909.92%. Aclaris Therapeutics' overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current FCF Margin % is -909.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (ACRS) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $4.85 is trading 976.7% above its estimated GF Value™ of $0.45.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for ACRS:
FCF Margin %: -909.92%
GF Value™: $0.45 vs. price of $4.85 (976.7% above fair value)
No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score
Get the complete analysis for ACRS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRS has been successfully added to your 
